Advanced Biomed (ADVB) closed at $2.10 on November 4, 2026, down 4.5% from the previous close, on volume of 25,100 shares (30-day average 30,992).
Data as of November 4, 2026.
No headlines found.
No press releases found.
No news found.
Advanced Biomed Inc operates through its subsidiary as an AI financial verification company focused on financial verification and other professional, regulated use cases. The Group develops and operates the FinTruth Financial Verification Agent Platform (FinTruth), an enterprise AI financial verification platform designed to compare and verify financial analysis and AI-generated financial content against underlying source documents and financial rules, and to produce source-traceable and auditable results. It focuses on establishing recurring and usage-based enterprise revenue from its AI technology operations. The Group has one reportable segment, consisting mainly of its technology and software-related operations.
Advanced Biomed trades on the NASDAQ stock market under the symbol ADVB.
As of November 5, 2026, ADVB stock price declined to $1.87 with 10,428 million shares trading.
ADVB has a beta of 1.51, meaning it tends to be more sensitive to market movements. ADVB has a correlation of 0.01 to the broad based SPY ETF.
ADVB has a market cap of $3.09 million. This is considered a Sub-Micro Cap stock.
ADVB has underperformed the market in the last year with a price return of -79.5% while the SPY ETF gained +11.5%. ADVB has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -76.6% and -50.3%, respectively, while the SPY returned -3.1% and -3.6%, respectively.
ADVB support price is $1.81 and resistance is $2.39 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADVB shares will trade within this expected range on the day.
